The m6A modification of SOX18 leads to increased PTX3 and cardiomyocyte pyroptosis in sepsis-induced cardiomyopathy
Theranostics · 24.02.2025 · 15 (8) · 3532-3550
DOI: 10.7150/thno.103809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 24.02.2025. Verfasst von He Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, 127 Changle West Road, Xi'an, Shaanxi 710032, …. Hauptthemen laut MEDLINE: Pyroptosis, Myocytes, Cardiac, Cardiomyopathies, Sepsis. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Sepsis
Abstract (Originalsprache)
Rationale
Sepsis-induced cardiomyopathy (SIC) is a rapidly progressing condition with poor prognosis in the absence of effective therapeutic interventions.Cardiomyocyte pyroptosis is a critical factor contributing to cardiac dysfunction in SIC.Currently, research on this mechanism remains unclear.
Methods
We performed LPS-induced primary mouse cardiomyocyte modeling and mouse SIC modeling.Through mRNA-Seq, we found significant pyroptosis in the cardiac tissue of SIC mice.Further confocal microscopy and immunoprecipitation results confirmed that PTX3 is an important participant in cardiomyocyte pyroptosis.We then used ChIP and dual-luciferase reporter assays to confirm that SOX18 exerts a transcriptional repression effect on PTX3.M6A-Seq and RNA stability assays confirmed that the m6A modification mediated/recognized by RBM15/YTHDF2 is a crucial factor in the changes of SOX18 in SIC.
Results
Our experiments demonstrated that the abnormally elevated PTX3 in SIC plays a key role in mediating pyroptosis.Under physiological conditions, PTX3 transcription is repressed by SOX18.However, during septic cardiomyopathy, SOX18 stability is compromised by RBM15/YTHDF2-mediated m6A modification, leading to increased PTX3 levels and the subsequent induction of cardiomyocyte pyroptosis.
Conclusion
In summary, we have delineated the RBM15/YTHDF2-SOX18-PTX3 axis in SIC.It provides a new approach for the treatment of cardiomyocyte pyroptosis in SIC and for improving prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, The First Affiliated Hospital, The Air Force Medical University, 127 Changle West Road, Xi'an, Shaanxi 710032, China.
- School of Medicine, Northwest University, Xi'an, Shaanxi 710069, China.
- Department of Surgery, The 954th Hospital of the Chinese People's Liberation Army, Shannan, Tibet 856100, China.
Zitieren
APA
Sun, H., Qiao, X., Peng, X., Zhu, H., Zhang, L., Jiang, L., Wang, L., Xue, C., Yang, J., Yi, W., Zhang, B., Liu, J., & Duan, W. (2025). The m6A modification of SOX18 leads to increased PTX3 and cardiomyocyte pyroptosis in sepsis-induced cardiomyopathy. Theranostics, 15(8), 3532-3550. https://doi.org/10.7150/thno.103809
Vancouver
Sun H, Qiao X, Peng X, Zhu H, Zhang L, Jiang L, et al. The m6A modification of SOX18 leads to increased PTX3 and cardiomyocyte pyroptosis in sepsis-induced cardiomyopathy. Theranostics. 2025;15(8):3532-3550. doi:10.7150/thno.103809
BibTeX
@article{Sun2025,
author = {Sun, He and Qiao, Xinan and Peng, Xiangyan and Zhu, Hanzhao and Zhang, Liyun and Jiang, Liqing and Wang, Longteng and Xue, Chao and Yang, Jian and Yi, Wei and Zhang, Bin and Liu, Jincheng and Duan, Weixun},
title = {The m6A modification of SOX18 leads to increased PTX3 and cardiomyocyte pyroptosis in sepsis-induced cardiomyopathy},
journal = {Theranostics},
year = {2025},
volume = {15},
number = {8},
pages = {3532--3550},
doi = {10.7150/thno.103809}
}
EUVIMED